374 related articles for article (PubMed ID: 16688372)
1. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
2. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
[TBL] [Abstract][Full Text] [Related]
3. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
[TBL] [Abstract][Full Text] [Related]
4. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
7. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
8. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.
Kita T; Kikuchi Y; Takano M; Suzuki M; Oowada M; Konno R; Yamamoto K; Inoue H; Seto H; Yamamoto T; Shimizu K
Gynecol Oncol; 2004 Mar; 92(3):813-8. PubMed ID: 14984946
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
[TBL] [Abstract][Full Text] [Related]
10. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
11. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Grønlund B
Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
[No Abstract] [Full Text] [Related]
12. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
13. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
[TBL] [Abstract][Full Text] [Related]
15. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
[TBL] [Abstract][Full Text] [Related]
16. CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?
Davelaar EM; Bonfrer JM; Verstraeten RA; ten Bokkel Huinink WW; Kenemans P
Cancer; 1996 Jul; 78(1):118-27. PubMed ID: 8646707
[TBL] [Abstract][Full Text] [Related]
17. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
[TBL] [Abstract][Full Text] [Related]
18. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
19. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
[TBL] [Abstract][Full Text] [Related]
20. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]